Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether Arcoxia is effective in preventing heterotopic ossification after total hip arthroplasty.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radboud University
• Treatments: Etoricoxib

Criteria

Inclusion Criteria:

• Patients with primary or secondary hip osteoarthritis who are scheduled for cemented total hip replacement at the Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.

• Written informed consent is obtained from the patient or the legally accepted representative.

Exclusion Criteria:

• Patients with rheumatoid arthritis, ankylosing spondylitis, or femoral neck fractures

• Patients with previous allergic reaction on non-steroidal anti-inflammatory drugs

• Patients with gastrointestinal complaints at admission, a history of gastrointestinal ulcers or perforations, inflammatory bowel-disease, hepatic dysfunction, renal dysfunction with a clearance below 30 ml/min and cardiac insufficiency.

• Patients with blood pressure consistently > 140/90 mmHg and who have not been adequately controlled.